期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PI_3K/AKT信号转导通路在乳腺癌转移和耐药中的研究 被引量：5

Study of PI_3K/AKT Signaling Transduction Pathway in Breast Cancer Metastasis and Drug Fast
下载PDF
导出
摘要 磷脂酰肌醇-3-激酶/丝苏氨酸蛋白激酶(PI3K/AKT)信号转导通路作为细胞生长增殖的重要转导通路,在维持细胞恶性生物学特性中起重要作用。细胞在一系列内外因素的作用下,通过启动PI3K/AKT信号转导通路,诱导细胞的增殖、分化,避免细胞发生凋亡。近年来研究表明,PI3K/AKT信号转导通路在肿瘤细胞恶性增殖、血管新生和转移以及对放化疗的拮抗中起着重要作用。文章主要综述PI3K/AKT信号转导通路的结构特点,及其在乳腺癌转移与耐药中的作用。 The PI3K/AKT signal transduetion pathway is an inportant pathway in cell growth and prohferation,whieh plays an important role in keeping malignant bionomics of cells. Under a series of exterior and interior factors, cells proliferation and, differentiation can be, induced and cell apoptosis can be avoided by initiating PI3 K/ AKT pathway. Recent studies indicate that this pathway plays an important role in tumor cells proliferation, blood vessel neogenesis, tumor metastasis and resistance to chemotherapy and radiotherapy. This article mainly reviews the structure feature of PI3 K/AKT and its effect in metastasis and drug fast of breast cancer.
作者 李小芳 姜汉国
机构地区 广东医学院病理教研室
出处 《医学综述》 2008年第3期355-357,共3页 Medical Recapitulate
关键词 乳腺肿瘤 肿瘤转移 信号转导通路 化疗耐药 Breast cancer Tumor metastasis Signaling transduction pathway Resistance to chemotherapy
分类号 R737.9 [医药卫生—肿瘤] R73-37 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Hill K,Welti S, Yu J, et al.Specific requirement for the p85 p110 alpha phosphatidylinositol 3-kinase during epidermal growth factor stimulated actin nucleation in breast cancer cells[J]. J Biol Chem, 2000, 275 (6) : 3741-3744.
  • 2Zhang GX, He B, Weber GF, et al. Growth factor signaling induces metastasis genes in transformed cells: molectdar connection between Akt kinase and osteopontin in breast cancer[J]. Mol Cell Biol, 2003,23 (18) :6507-6519.
  • 3Skurk C, Maatz H, Rocnik E, et al. Glycogen-Synthase Kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells[J]. Circ Res, 2005,96(3) :308-318.
  • 4高杰,刘执玉,毕玉顺,田铧.血管内皮生长因子CmRNA在人乳腺癌细胞株中的表达[J].山东大学学报（医学版）,2002,40(3):219-221. 被引量：6
  • 5Li YS, Kaneko M, Amatya VJ, et al. Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma of the breast [ J]. Pathol Int, 2006,56 (5) : 256-261.
  • 6Tang YC, Zhang DL, Faliavollita L, etal. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor[ J ]. Cancer Res, 2003,63 (6) : 1166-1171.
  • 7朱丽,周永昌,李亚芬,鲁庆荣,朱正纲,李宏为.PTEN抑癌基因在乳腺癌组织中的表达及其与乳腺癌微小转移灶的关系[J].外科理论与实践,2005,10(4):360-363. 被引量：3
  • 8Vogel CL, Cobleigh MA,Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer[J] .J Clin Oncol,2002,20(3):719-726.
  • 9Clark AS, West K, Streicher S, et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells[ J]. Mol Cancer Ther, 2002,1 (9) :707-717.
  • 10Nahta R, Takahashi T, Ueno NT, et al. 1727 ( kipl ) down-regulation is associated with trastuzumab resistance in breast cancer cells[J]. Cancer Res, 2004,64( 11 ) : 3981-3986.

二级参考文献10

  • 1Kenneth JL, and Thomas DS. Analysis of relative gene expression data using real-time quantitative PCR and the 2^-△△α method[J]. Method, 2001,25:402-408.
  • 2Schoenfeld A, Kruger KH, Gomm J, Sinnett HD, Gazet JC, Sacks N, Bender HG, Luqmani Y, and Coombes RC.The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19[J]. Eur J Cancer, 1997,33:854-61.
  • 3Ridell B and Lansky K. Incidence and histopathology of metastases of mammry carcinoma in biopsies form the posterior iliac crest[J]. Cancer, 1979,44:1782-7.
  • 4International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastasis from breast cancer[J]. Lancet, 1990,335:1565-1568.
  • 5Dowlatshali K, Witt TR, Bloom K J, et al. Detection of occult micrometastasis by 0.25 mm sectioning and cytokeratin staining of sentinel nodes in early breast cancer.Proceedings of the American Society of Clinical Oncology, 36th Annual Meeting, New Orleans 2000 (Abstract 305, vol. 19).
  • 6Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer[J]. Mod Pathol, 2001,14:672-676.
  • 7Freihoff D, Kempe A, Beste B, et al. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas[J]. Br J Cancer, 1999,79:754-758.
  • 8Bose S, Crane A, Hibshoosh H, et al. Reduced expression of PTEN correlates with breast cancer progression[J]. Human Pathol, 2002,33(4):405-409.
  • 9武正炎 杜竞辉 毛力 等.免疫组化方法检测乳腺癌患者骨髓内转移癌细胞[J].南京医学院学报,1989,9(4):296-297.
  • 10高杰.血管内皮生长因子C的研究进展[J].国外医学（分子生物学分册）,2000,22(3):162-166. 被引量：16

共引文献7

同被引文献75

  • 1朱丽,周永昌,李亚芬,鲁庆荣,朱正纲,李宏为.PTEN抑癌基因在乳腺癌组织中的表达及其与乳腺癌微小转移灶的关系[J].外科理论与实践,2005,10(4):360-363. 被引量：3
  • 2孙晓杰,黄常志.PI3K-Akt信号通路与肿瘤[J].世界华人消化杂志,2006,14(3):306-311. 被引量：80
  • 3胡蕾,姜汉国.PI3K/AKT信号转导通路与肿瘤转移及其机制的研究进展[J].医学综述,2006,12(22):1375-1377. 被引量：18
  • 4Wong KK, Fracasso PM, Bukowski RM, et al. A phase Ⅰ study with oeratinib (HKI-272) ,an irreversible pan ErbB receptor tyrosine kinase inhibitor,in patients with solid tumors [ J ]. Clin Cancer Res,2009,15 (7) :2552-2558.
  • 5Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors[ J]. Curt Opin Investig Drugs,2008,9(12) :1336-1346.
  • 6Pegram M. Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways? [ J ]. Clin Breast Cancer, 2008, ( 8 Suppl 3) :121-130.
  • 7Howes AL, Chiang GG, Lang ES, et al. The phosphatidylinositol 3- kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures[ J]. Mol Cancer Ther, 2007,6(9) :2505-2514.
  • 8Leighl NB, Dent S, Clemons M, et al. A Phase 2 study of perifosine in advanced or metastatic breast cancer [ J ]. Breast Cancer Res Treat ,2008,108 ( 1 ) :87-92.
  • 9LoPiceolo J, Blumentbal GM. Targeting the PIK/Akt/mTOR pathway : effective combinations and clinical considerations [ J ]. Drug Resist Updat ,2008,11 ( 1/2 ) :32-50.
  • 10Treeck O, Wackwitz B, Hans U, et al. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells [ J ]. Gynecol Oncol, 2006,102 ( 2 ) : 292 -299.

引证文献5

二级引证文献17

医学综述
2008年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部